share_log

8-K: SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update

SEC ·  Nov 13, 2024 22:18

Summary by Moomoo AI

SeaStar Medical reported its first commercial revenue of $67,500 in Q3 2024 from direct QUELIMMUNE sales, following FDA clearance in February 2024. The company has transitioned to a direct sales model in October, expecting to recognize full revenue value from end-user sales going forward. Additionally, the company shipped product worth approximately $70,000 to its former distribution partner.The NEUTRALIZE-AKI pivotal trial for adult patients has enrolled 59 subjects, with three new medical centers joining in Q4, bringing the total to 12 sites. The company received its fourth FDA Breakthrough Device Designation for the SCD in chronic dialysis indication. Financial highlights include the elimination of over $9 million in long-term debt since early 2024.Q3 2024 financial results showed R&D expenses of $2.3 million and G&A expenses of $2.2 million. The net loss was $4.5 million ($1.10 per share), compared to $7.2 million ($9.02 per share) in Q3 2023. Cash position stood at $2.1 million as of September 30, 2024, bolstered by a $10 million registered direct offering in July 2024.
SeaStar Medical reported its first commercial revenue of $67,500 in Q3 2024 from direct QUELIMMUNE sales, following FDA clearance in February 2024. The company has transitioned to a direct sales model in October, expecting to recognize full revenue value from end-user sales going forward. Additionally, the company shipped product worth approximately $70,000 to its former distribution partner.The NEUTRALIZE-AKI pivotal trial for adult patients has enrolled 59 subjects, with three new medical centers joining in Q4, bringing the total to 12 sites. The company received its fourth FDA Breakthrough Device Designation for the SCD in chronic dialysis indication. Financial highlights include the elimination of over $9 million in long-term debt since early 2024.Q3 2024 financial results showed R&D expenses of $2.3 million and G&A expenses of $2.2 million. The net loss was $4.5 million ($1.10 per share), compared to $7.2 million ($9.02 per share) in Q3 2023. Cash position stood at $2.1 million as of September 30, 2024, bolstered by a $10 million registered direct offering in July 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 240

Recommended

Related Stocks Related Stocks
Symbol Mini Chart Price
BioXcel Therapeutics
BTAI
3.750
BioCardia
BCDA
2.560
Entero Therapeutics
ENTO
0.610
Exicure
XCUR
11.3200
Aldeyra Therapeutics
ALDX
6.060
Log In for the Full List
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve Show More
Can Big Tech earnings ignite the markets again?
85%
15%
Yes
No
5169 votes
AMZN earnings preview: Grab rewards by guessing the opening price!
Hi mooers!
With the development of e-commerce and cloud computing, $Amazon (AMZN.US)$ has attracted widespread market attention. It is releasing its last quarter earnings on February 6th after bell.
Unlock insights with AMZN Earnings Hub>>
Rewards
● An equal share of 5,000 points: For mooers who correctly guess the winner who makes the biggest %gains in intraday trading on the first day after their earnings (e.g., If 50 mooers ma...